ArticleCancer immunology, immunotherapy : CII2023

BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.

Kan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.